SlideShare ist ein Scribd-Unternehmen logo
1 von 15
Strategic responsiveness  of the survivors of Big Pharma companies Amit Rangnekar NMIMS-PhD-2004 DIIS Seminar, Copenhagen 2 nd  October, 2006
Industry Brief Pharmacies Takeda Pharmacies , dyes  Roche,  Hoechst, Ciba, Sandoz Pharmacies , dyes  Wyeth, BMS, Lilly , Merck, Pfizer,  Origin Cost controls Price controls, non harmonisation Pricing, marketing, innovation,generics Drivers / resistors 11% 29% 44%  Market share Dominant,  8 of the top 10, account for 75% of local sales More US sales (43%) than European (34%), except SanofiAventis Strong US sales (60%), but  low Europe sales (25%) Local companies Pharma Takeda, Sankyo Chemicals,agro,dyes, drugs, OTC-  Hoechst, Bayer, Ciba, Sandoz Pharma, healthcare  Pfizer, Merck, Wyeth, J&J Traditional focus on Japan Europe US
Key Growth Elements In Top 10 Markets IMS-Health MIDAS, December, 2005 9.1 2.5 4.3 2.3 Average 5.7 2.3 1.8 1.6 2005 7.2 2.3 2.7 2.2 2004 10 2.6 4.5 2.9 2003 9.2 2.6 4.3 2.3 2002 13.4 2.8 8.1 2.5 2001 Total New Products Volumes Price Year
Dynamics of the 21st century pharma ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],?
Big Pharma Marketshare (1995-2004) Strivers
Big Pharma v/s World Pharma Growth % World pharma growth (%) Big pharma growth (%) Big Pharma on an average, has grown at 67% more than  the world pharma industry growth rate between 1995 and 2004
Big Pharma- Growing dominance ,[object Object],[object Object],[object Object],[object Object]
Big Pharma driven strategic Shifts ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Big Pharma Survivors (In red) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Big Pharma 2004- Market shares since 1997 Survivors of Big Pharma Other Big Pharma
Big Pharma Geographical Ranking 4 10 10 29 47 WMS % Novartis Pfizer Pfizer GSK GSK No 2 GSK Pfizer Latin America Novartis GSK Asia  (minus Japan) Astellas Takeda Japan Novartis SanofiAventis Europe J&J Pfizer North America No 3 No 1 Region
Increasing Pharma Focus (%) ,[object Object],[object Object]
Strategies of Survivors  Use of strategy:  High  +++ , Moderate  ++ , Low  + ++ ++ Strategic stake Novartis Roche GSK BMS Merck Pfizer + +++ ++ Eur +++ + + US +++ ++ +++ ++ Organic growth + + Co-promotion + + Eur ++ Eur + US ++ +++ US Alliances M&A Origin
Performance differentiators of Survivors  Impact of strategy:  Maximum  +++ , Moderate  ++ , Minimum  + ++ +++ + +++ ++ Eur Novartis Eur Eur US US US Origin +++ ++ + ++ +++ Key  segment presence ++ +++ + ++ +++ Block Busters + ++ +++ +++ +++ Patent  threats +++ ++ Roche ++ +++ GSK + + BMS ++ ++ Merck + ++ Pfizer Lucrative Niche presence  New  Drugs
[object Object],[object Object],[object Object],Key facts 1995-2004

Weitere ähnliche Inhalte

Was ist angesagt?

Pharmaceutical Industry Overview
Pharmaceutical Industry OverviewPharmaceutical Industry Overview
Pharmaceutical Industry OverviewDemetris Iacovides
 
Future Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challengesFuture Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challengesscottosur
 
CFA_Research_Challenge_Report_ESRX_TEAM-A1
CFA_Research_Challenge_Report_ESRX_TEAM-A1CFA_Research_Challenge_Report_ESRX_TEAM-A1
CFA_Research_Challenge_Report_ESRX_TEAM-A1David Shoko
 
Rbsa pharmaceutical industry analysis
Rbsa   pharmaceutical industry analysisRbsa   pharmaceutical industry analysis
Rbsa pharmaceutical industry analysisNachiket Kadu
 
Pharmaceutical Company Analysis
Pharmaceutical Company AnalysisPharmaceutical Company Analysis
Pharmaceutical Company AnalysisDaniel James
 
GLOBAL PHARMACEUTICAL INDUSTRY
GLOBAL PHARMACEUTICAL INDUSTRYGLOBAL PHARMACEUTICAL INDUSTRY
GLOBAL PHARMACEUTICAL INDUSTRYDhanil Francil
 
Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018lakshmipraneethganti
 
Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...
Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...
Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...Canadian Cancer Survivor Network
 
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
 
Business Plan- TLG Resources International LLC
Business Plan- TLG Resources International LLCBusiness Plan- TLG Resources International LLC
Business Plan- TLG Resources International LLCnroopraj24
 
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)Steven Sabo
 
Emerging trends in pharmaceutical industry 2012
Emerging trends in pharmaceutical industry 2012Emerging trends in pharmaceutical industry 2012
Emerging trends in pharmaceutical industry 2012Ourania Koumi
 

Was ist angesagt? (19)

Pharmaceutical Industry Overview
Pharmaceutical Industry OverviewPharmaceutical Industry Overview
Pharmaceutical Industry Overview
 
Future Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challengesFuture Pharma Trends - Long-term opportunities tempered by short-term challenges
Future Pharma Trends - Long-term opportunities tempered by short-term challenges
 
Final Ib Ranbaxy
Final Ib RanbaxyFinal Ib Ranbaxy
Final Ib Ranbaxy
 
Medco (MHS) Bench
Medco (MHS) BenchMedco (MHS) Bench
Medco (MHS) Bench
 
CFA_Research_Challenge_Report_ESRX_TEAM-A1
CFA_Research_Challenge_Report_ESRX_TEAM-A1CFA_Research_Challenge_Report_ESRX_TEAM-A1
CFA_Research_Challenge_Report_ESRX_TEAM-A1
 
gild_s16
gild_s16gild_s16
gild_s16
 
Rbsa pharmaceutical industry analysis
Rbsa   pharmaceutical industry analysisRbsa   pharmaceutical industry analysis
Rbsa pharmaceutical industry analysis
 
Pharmaceutical Company Analysis
Pharmaceutical Company AnalysisPharmaceutical Company Analysis
Pharmaceutical Company Analysis
 
GLOBAL PHARMACEUTICAL INDUSTRY
GLOBAL PHARMACEUTICAL INDUSTRYGLOBAL PHARMACEUTICAL INDUSTRY
GLOBAL PHARMACEUTICAL INDUSTRY
 
Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018Pharmaceutical drugs global market report 2018
Pharmaceutical drugs global market report 2018
 
Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...
Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...
Patented Medicine Prices Review Board: Exploring the Impact of Proposed Price...
 
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...
 
Business Plan- TLG Resources International LLC
Business Plan- TLG Resources International LLCBusiness Plan- TLG Resources International LLC
Business Plan- TLG Resources International LLC
 
Case study on merck
Case study on merckCase study on merck
Case study on merck
 
The changing biopharma risk equation
The changing biopharma risk equationThe changing biopharma risk equation
The changing biopharma risk equation
 
Pharmaceutical Supply Chain Dynamics and Intelligence
Pharmaceutical Supply Chain Dynamics and IntelligencePharmaceutical Supply Chain Dynamics and Intelligence
Pharmaceutical Supply Chain Dynamics and Intelligence
 
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
Pharmaceutical Industry Environmental Analysis (Sanofi, Merck & Co.)
 
Emerging trends in pharmaceutical industry 2012
Emerging trends in pharmaceutical industry 2012Emerging trends in pharmaceutical industry 2012
Emerging trends in pharmaceutical industry 2012
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
 

Andere mochten auch

Merck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare ConferenceMerck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare ConferenceKishan Soni
 
Healthcare and Business Advantage: the Case of Sanofi
Healthcare and Business Advantage: the Case of SanofiHealthcare and Business Advantage: the Case of Sanofi
Healthcare and Business Advantage: the Case of SanofiJoseph Pategou
 
Competitive advantage and strategy formulation process
Competitive advantage and strategy formulation processCompetitive advantage and strategy formulation process
Competitive advantage and strategy formulation processvitusmaren
 
Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...
Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...
Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...Global Business Events
 
PharmaBrand Summit 2012: Presentation by Professor Brian D Smith
PharmaBrand Summit 2012: Presentation by Professor Brian D SmithPharmaBrand Summit 2012: Presentation by Professor Brian D Smith
PharmaBrand Summit 2012: Presentation by Professor Brian D SmithMarketing Network marcus evans
 
TRUST US: WE’RE THE TOBACCO INDUSTRY
TRUST US:  WE’RE THE TOBACCO INDUSTRYTRUST US:  WE’RE THE TOBACCO INDUSTRY
TRUST US: WE’RE THE TOBACCO INDUSTRYCláudio Carneiro
 
Lobbying as a promotional tool
Lobbying as a promotional toolLobbying as a promotional tool
Lobbying as a promotional toolkranthi227
 
Walmart lobbying in India 2014
Walmart lobbying in India 2014Walmart lobbying in India 2014
Walmart lobbying in India 2014Abhishek Jain
 
Porter's Five Forces of pharmaceutical industry in Myanmar
Porter's Five Forces of pharmaceutical industry in MyanmarPorter's Five Forces of pharmaceutical industry in Myanmar
Porter's Five Forces of pharmaceutical industry in MyanmarPhyo Paing (Derek)
 
Apple Porter's five force model
Apple Porter's five force modelApple Porter's five force model
Apple Porter's five force modelRishabh RJ
 
Bayer HealthCare Overview
Bayer HealthCare OverviewBayer HealthCare Overview
Bayer HealthCare Overviewbhcbelgium
 
FY/Q4 2016 Investor Conference Call Presentation
FY/Q4 2016 Investor Conference Call PresentationFY/Q4 2016 Investor Conference Call Presentation
FY/Q4 2016 Investor Conference Call PresentationBayer
 

Andere mochten auch (20)

Merck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare ConferenceMerck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
Merck Revenue Growth Plan - Wharton Undergraduate Healthcare Conference
 
Healthcare and Business Advantage: the Case of Sanofi
Healthcare and Business Advantage: the Case of SanofiHealthcare and Business Advantage: the Case of Sanofi
Healthcare and Business Advantage: the Case of Sanofi
 
Competitive advantage and strategy formulation process
Competitive advantage and strategy formulation processCompetitive advantage and strategy formulation process
Competitive advantage and strategy formulation process
 
Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...
Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...
Paula Gildert, VP Development Strategic Sourcing at Novartis - Strategic valu...
 
The Dabbawallas
The DabbawallasThe Dabbawallas
The Dabbawallas
 
PharmaBrand Summit 2012: Presentation by Professor Brian D Smith
PharmaBrand Summit 2012: Presentation by Professor Brian D SmithPharmaBrand Summit 2012: Presentation by Professor Brian D Smith
PharmaBrand Summit 2012: Presentation by Professor Brian D Smith
 
TRUST US: WE’RE THE TOBACCO INDUSTRY
TRUST US:  WE’RE THE TOBACCO INDUSTRYTRUST US:  WE’RE THE TOBACCO INDUSTRY
TRUST US: WE’RE THE TOBACCO INDUSTRY
 
Novartis india
Novartis indiaNovartis india
Novartis india
 
Lobbying as a promotional tool
Lobbying as a promotional toolLobbying as a promotional tool
Lobbying as a promotional tool
 
Tobacco industry
Tobacco industryTobacco industry
Tobacco industry
 
Module 7 - Lobbying
Module 7 - LobbyingModule 7 - Lobbying
Module 7 - Lobbying
 
Walmart lobbying in India 2014
Walmart lobbying in India 2014Walmart lobbying in India 2014
Walmart lobbying in India 2014
 
B2 novartis
B2 novartisB2 novartis
B2 novartis
 
Porter's Five Forces of pharmaceutical industry in Myanmar
Porter's Five Forces of pharmaceutical industry in MyanmarPorter's Five Forces of pharmaceutical industry in Myanmar
Porter's Five Forces of pharmaceutical industry in Myanmar
 
McDonalds India launch
McDonalds India launchMcDonalds India launch
McDonalds India launch
 
Pharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the OpportunitiesPharmaceutical Industry: The Challenges and the Opportunities
Pharmaceutical Industry: The Challenges and the Opportunities
 
Philip Morris USA
Philip Morris USAPhilip Morris USA
Philip Morris USA
 
Apple Porter's five force model
Apple Porter's five force modelApple Porter's five force model
Apple Porter's five force model
 
Bayer HealthCare Overview
Bayer HealthCare OverviewBayer HealthCare Overview
Bayer HealthCare Overview
 
FY/Q4 2016 Investor Conference Call Presentation
FY/Q4 2016 Investor Conference Call PresentationFY/Q4 2016 Investor Conference Call Presentation
FY/Q4 2016 Investor Conference Call Presentation
 

Ähnlich wie Global Pharmaceutical Strategy

The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009shajijohnvanilla
 
The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009shajanjohnvanilla
 
Weekly Health Care News No.3 (2016-03-20)
Weekly Health Care News No.3 (2016-03-20)Weekly Health Care News No.3 (2016-03-20)
Weekly Health Care News No.3 (2016-03-20)Harald Schelenz
 
Pharmaceutical Drugs Essay
Pharmaceutical Drugs EssayPharmaceutical Drugs Essay
Pharmaceutical Drugs EssayNicole Williams
 
Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008Sheetal Narkar
 
Genzyme Corporation: PharmaVitae Profile
Genzyme Corporation: PharmaVitae ProfileGenzyme Corporation: PharmaVitae Profile
Genzyme Corporation: PharmaVitae ProfileReportLinker.com
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Global Study Solutions - 9901366442
 
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Aiswariya Chidambaram
 
The Security Of Pharmaceutical Use Essay
The Security Of Pharmaceutical Use EssayThe Security Of Pharmaceutical Use Essay
The Security Of Pharmaceutical Use EssayNavy Savchenko
 
Top 10 biotech companies & market share 2008
Top 10 biotech companies & market share 2008Top 10 biotech companies & market share 2008
Top 10 biotech companies & market share 2008Akumentis Healthcare Ltd
 
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisGlobal Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisAiswariya Chidambaram
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryYee Jie NG
 
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. Shantanu Kumar Singh
 
SWOT Analysis of Sunpharma
SWOT Analysis of SunpharmaSWOT Analysis of Sunpharma
SWOT Analysis of SunpharmaPratik Rahate
 
Introduction to the pharmaceutical market and practice
Introduction to the pharmaceutical market and practiceIntroduction to the pharmaceutical market and practice
Introduction to the pharmaceutical market and practiceWayne Wei
 
Global Injectable Generic Market
Global Injectable Generic MarketGlobal Injectable Generic Market
Global Injectable Generic Marketritupon gogoi
 

Ähnlich wie Global Pharmaceutical Strategy (20)

The Future of the Pharmaceutical Industry in Spain
The Future of the Pharmaceutical Industry in SpainThe Future of the Pharmaceutical Industry in Spain
The Future of the Pharmaceutical Industry in Spain
 
The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009
 
The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009
 
Weekly Health Care News No.3 (2016-03-20)
Weekly Health Care News No.3 (2016-03-20)Weekly Health Care News No.3 (2016-03-20)
Weekly Health Care News No.3 (2016-03-20)
 
Pharmaceutical Drugs Essay
Pharmaceutical Drugs EssayPharmaceutical Drugs Essay
Pharmaceutical Drugs Essay
 
Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008Top 10 Biotech Companies & Market Share 2008
Top 10 Biotech Companies & Market Share 2008
 
Genzyme Corporation: PharmaVitae Profile
Genzyme Corporation: PharmaVitae ProfileGenzyme Corporation: PharmaVitae Profile
Genzyme Corporation: PharmaVitae Profile
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
 
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
Global Biopharmaceutical Contract Manufacturing Market - Qualitative and Quan...
 
The Security Of Pharmaceutical Use Essay
The Security Of Pharmaceutical Use EssayThe Security Of Pharmaceutical Use Essay
The Security Of Pharmaceutical Use Essay
 
Top 10 biotech companies & market share 2008
Top 10 biotech companies & market share 2008Top 10 biotech companies & market share 2008
Top 10 biotech companies & market share 2008
 
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisGlobal Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical Industry
 
Bayer(benazir)
Bayer(benazir)Bayer(benazir)
Bayer(benazir)
 
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
 
SWOT Analysis of Sunpharma
SWOT Analysis of SunpharmaSWOT Analysis of Sunpharma
SWOT Analysis of Sunpharma
 
Introduction to the pharmaceutical market and practice
Introduction to the pharmaceutical market and practiceIntroduction to the pharmaceutical market and practice
Introduction to the pharmaceutical market and practice
 
Pharmacy Presentation
Pharmacy PresentationPharmacy Presentation
Pharmacy Presentation
 
Global Injectable Generic Market
Global Injectable Generic MarketGlobal Injectable Generic Market
Global Injectable Generic Market
 
India and global generics M&A Summary 2007
India and global generics M&A Summary 2007India and global generics M&A Summary 2007
India and global generics M&A Summary 2007
 

Kürzlich hochgeladen

MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentationbaron83
 
Human Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and AppraisalHuman Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and Appraisalgomezdominic3
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023Steve Rader
 
Project Brief & Information Architecture Report
Project Brief & Information Architecture ReportProject Brief & Information Architecture Report
Project Brief & Information Architecture Reportamberjiles31
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursKaiNexus
 
מיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגלי
מיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגלימיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגלי
מיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגליBen Shushan & Co. C.P.A (Isr.)
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsyasinnathani
 
Transform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in LauncestonTransform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in Launcestondjhbuildersau
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhangmcgroupjeya
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyHanna Klim
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examplesamberjiles31
 
Fabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsFabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsWristbands Ireland
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxWorkforce Group
 
Six Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating PerformanceSix Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating PerformanceOperational Excellence Consulting
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfHajeJanKamps
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHelene Heckrotte
 

Kürzlich hochgeladen (20)

MoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor PresentationMoneyBridge Pitch Deck - Investor Presentation
MoneyBridge Pitch Deck - Investor Presentation
 
Human Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and AppraisalHuman Resource Management Chapter 9: Performance Management and Appraisal
Human Resource Management Chapter 9: Performance Management and Appraisal
 
NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023NASA CoCEI Scaling Strategy - November 2023
NASA CoCEI Scaling Strategy - November 2023
 
Project Brief & Information Architecture Report
Project Brief & Information Architecture ReportProject Brief & Information Architecture Report
Project Brief & Information Architecture Report
 
Developing Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, OursDeveloping Coaching Skills: Mine, Yours, Ours
Developing Coaching Skills: Mine, Yours, Ours
 
AL Satwa Dubai Call Girls +971552825767 Call Girls In AL Karama
AL Satwa Dubai Call Girls +971552825767  Call Girls In AL KaramaAL Satwa Dubai Call Girls +971552825767  Call Girls In AL Karama
AL Satwa Dubai Call Girls +971552825767 Call Girls In AL Karama
 
Deira Dubai Call Girls +971552825767 Call Girls In Downtown Dubai
Deira Dubai Call Girls +971552825767 Call Girls In Downtown DubaiDeira Dubai Call Girls +971552825767 Call Girls In Downtown Dubai
Deira Dubai Call Girls +971552825767 Call Girls In Downtown Dubai
 
מיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגלי
מיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגלימיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגלי
מיסוי רילוקיישן לפורטוגל- היבטי מיסוי ישראלי ופורטוגלי
 
Data skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story pointsData skills for Agile Teams- Killing story points
Data skills for Agile Teams- Killing story points
 
Transform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in LauncestonTransform Your Kitchen Essential Tips for Renovations in Launceston
Transform Your Kitchen Essential Tips for Renovations in Launceston
 
Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024Borderless Access - Global Panel book-unlock 2024
Borderless Access - Global Panel book-unlock 2024
 
MC Heights construction company in Jhang
MC Heights construction company in JhangMC Heights construction company in Jhang
MC Heights construction company in Jhang
 
Anyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agencyAnyhr.io | Presentation HR&Recruiting agency
Anyhr.io | Presentation HR&Recruiting agency
 
Intellectual Property Licensing Examples
Intellectual Property Licensing ExamplesIntellectual Property Licensing Examples
Intellectual Property Licensing Examples
 
Fabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and FestivalsFabric RFID Wristbands in Ireland for Events and Festivals
Fabric RFID Wristbands in Ireland for Events and Festivals
 
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptxCracking the ‘Business Process Outsourcing’ Code Main.pptx
Cracking the ‘Business Process Outsourcing’ Code Main.pptx
 
Six Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating PerformanceSix Sigma Improvement Process: Transforming Processes, Elevating Performance
Six Sigma Improvement Process: Transforming Processes, Elevating Performance
 
PDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdfPDT 88 - 4 million seed - Seed - Protecto.pdf
PDT 88 - 4 million seed - Seed - Protecto.pdf
 
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
TalentView Webinar: Empowering the Modern Workforce_ Redefininig Success from...
 
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptxHELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
HELENE HECKROTTE'S PROFESSIONAL PORTFOLIO.pptx
 

Global Pharmaceutical Strategy

  • 1. Strategic responsiveness of the survivors of Big Pharma companies Amit Rangnekar NMIMS-PhD-2004 DIIS Seminar, Copenhagen 2 nd October, 2006
  • 2. Industry Brief Pharmacies Takeda Pharmacies , dyes Roche, Hoechst, Ciba, Sandoz Pharmacies , dyes Wyeth, BMS, Lilly , Merck, Pfizer, Origin Cost controls Price controls, non harmonisation Pricing, marketing, innovation,generics Drivers / resistors 11% 29% 44% Market share Dominant, 8 of the top 10, account for 75% of local sales More US sales (43%) than European (34%), except SanofiAventis Strong US sales (60%), but low Europe sales (25%) Local companies Pharma Takeda, Sankyo Chemicals,agro,dyes, drugs, OTC- Hoechst, Bayer, Ciba, Sandoz Pharma, healthcare Pfizer, Merck, Wyeth, J&J Traditional focus on Japan Europe US
  • 3. Key Growth Elements In Top 10 Markets IMS-Health MIDAS, December, 2005 9.1 2.5 4.3 2.3 Average 5.7 2.3 1.8 1.6 2005 7.2 2.3 2.7 2.2 2004 10 2.6 4.5 2.9 2003 9.2 2.6 4.3 2.3 2002 13.4 2.8 8.1 2.5 2001 Total New Products Volumes Price Year
  • 4.
  • 5. Big Pharma Marketshare (1995-2004) Strivers
  • 6. Big Pharma v/s World Pharma Growth % World pharma growth (%) Big pharma growth (%) Big Pharma on an average, has grown at 67% more than the world pharma industry growth rate between 1995 and 2004
  • 7.
  • 8.
  • 9.
  • 10. Big Pharma 2004- Market shares since 1997 Survivors of Big Pharma Other Big Pharma
  • 11. Big Pharma Geographical Ranking 4 10 10 29 47 WMS % Novartis Pfizer Pfizer GSK GSK No 2 GSK Pfizer Latin America Novartis GSK Asia (minus Japan) Astellas Takeda Japan Novartis SanofiAventis Europe J&J Pfizer North America No 3 No 1 Region
  • 12.
  • 13. Strategies of Survivors Use of strategy: High +++ , Moderate ++ , Low + ++ ++ Strategic stake Novartis Roche GSK BMS Merck Pfizer + +++ ++ Eur +++ + + US +++ ++ +++ ++ Organic growth + + Co-promotion + + Eur ++ Eur + US ++ +++ US Alliances M&A Origin
  • 14. Performance differentiators of Survivors Impact of strategy: Maximum +++ , Moderate ++ , Minimum + ++ +++ + +++ ++ Eur Novartis Eur Eur US US US Origin +++ ++ + ++ +++ Key segment presence ++ +++ + ++ +++ Block Busters + ++ +++ +++ +++ Patent threats +++ ++ Roche ++ +++ GSK + + BMS ++ ++ Merck + ++ Pfizer Lucrative Niche presence New Drugs
  • 15.